Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

GSK withdraws sNDA for Avodart as prostate cancer chemopreventative drug

March 10, 2010

Analysis of:GSK withdraws sNDA for prostate cancer drug Avodart | www.pharmabiz.com

Dutastaride (Avodart) has been used for treatment of symptomatic benign prostatic hypertrophy. It has been shown effective in reducing prostate volume, symptoms related to prostatic enlargement and PSA blood levels. Based on earlier data showing efficacy in prevention of prostate cancer development using 5 alpha-reductase inhibitors, a trial of dutastaride was undertaken.Chemoprevention using dutasteride: the REDUCE trial Curr Opin Urol. 2005 Jan;15(1):29-32www.ncbi.nlm.nih.gov/pubmed/15586026

Novexel position to be enhanced by AZ acquisition

January 8, 2010

Analysis of:Novexel acquisition by AstraZeneca a Win/Win | www.pipelinereview.com

Novexel focused on development of antibiotics to overcome problem of microbial drug resistanceNovexel shareholders agreed to be acquired by AstraZeneca for total consideration of $505 millionTransaction provides Novexel with cash and adds strong R&D philosophy which is part of the AZ cultureTransaction provides AZ with portfolio of clinical & preclinical compounds designed to address drug-resistant infectionspharmalicensing.com/public/news/viewNewsML/4185/Novexel_to_be_Acquired_by_AstraZeneca

TNF blockers linked to cancer risk in children & teens

August 5, 2009

Analysis of:TNF blockers linked to cancer risk in children & teens | benkazie.wordpress.com

The Food and Drug Administration said Tuesday there’s an increased risk of lymphoma and other cancers associated with the use of drugs like Remicade [infliximab] and Humira [adalimumab] in children and adolescents. The FDA is requiring stronger warnings regarding the risk for cancer associated with tumor necrosis factor (TNF) blockers.

Mortality risk low 15 years after radical prostatectomy

July 29, 2009

Analysis of:Mortality risk low 15 years after radical prostatectomy | benkazie.wordpress.com

http://benkazie.wordpress.com/2009/07/29/mortality-risk-low-15-years-after-radical-prostatectomy/ The fact remains that prostate cancer kills almost 30,000 men each year. It is also true that we are getting better at making more educated guesses regarding which men are most at risk to progress with prostate cancer. Finally, it has long been true that radical prostatectomy has been felt to be superior to all other forms of treatment in terms of achieving a long term cure of prostate cancer .

Tanning beds cause cancer

July 29, 2009

Analysis of:Tanning beds cause cancer | benkazie.wordpress.com

http://benkazie.wordpress.com/2009/07/29/quick-post-tanning-beds-may-cause-cancer/ Tanning beds pose as big a risk as tobacco and asbestos.

The Genie is Out of the Bottle

January 31, 2008

Analysis of:Nycomed and Wyeth announce launch of an own generic version of PROTONIX(R) | www.pipelinereview.com

- the fact is that the genie is out of the bottle - Protonix has long been viewed negatively by health plans due to cost - insurers are "forcing" subscribers to move to the generic version - thist further weakens patent protections .

Page : 11 to 6 of 6

Subscribe to Updates

By RSS